Medical Cannabis for Ulcerative Colitis — Switzerland 2026
Ulcerative colitis is chronic inflammatory. Intestinal CB2 receptors modulate inflammation — CBD & THC as add-on increasingly researched.
~15,000 people in Switzerland live with ulcerative colitis. Mesalazine, biologics (vedolizumab, ustekinumab) are standard. CB2 activation reduces cytokines — Naftali 2021 (RCT, n=32): CBD-rich oil significantly reduced Lichtiger index. Add-on in refractory disease. Members: 50 CHF instead of 190.
What the studies show
Naftali 2021: CBD oil 4.7 % over 10 weeks — significant quality-of-life improvement.
Irving 2018 (RCT, n=60): CBD-rich extract well-tolerated, fewer adverse events than placebo.
Preparations & dosing
Full-spectrum CBD oil 50–150 mg/day in 2 doses — anti-inflammatory.
THC 2.5–5 mg evenings for flare pain and sleep issues.
Save as a CannabisClub member
Gastroenterology cannabis consultation: 190–280 CHF. Members: 50 CHF flat, telemedicine. Registration free.
FAQ
Does cannabis replace my mesalazine?
No. Continue standard therapy — cannabis is add-on for residual symptoms or refractory disease.
What does membership save?
50 CHF instead of 190 CHF per consultation. Registration free.
Does insurance cover it?
Case by case art. 71a in refractory UC. Usually out of pocket.
Cannabis for Ulcerative Colitis — CBD & THC Switzerland 2026 (Members 50 CHF)